(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Central Nervous System Neoplasms
/ drug therapy
Deoxycytidine
/ administration & dosage
Disease-Free Survival
Female
Humans
Lymphoma
/ drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Organoplatinum Compounds
/ administration & dosage
Retrospective Studies
Rituximab
/ administration & dosage
Survival Rate
Chemotherapy
Primary central nervous system lymphoma
Recurrent
Refractory
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
20
08
2018
accepted:
19
11
2018
pubmed:
12
12
2018
medline:
26
3
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Recurrent primary central nervous system lymphomas (PCNSL) have a very poor prognosis. For young and fit patients, intensive chemotherapy followed by autologous stem cell transplantation could be proposed at relapse. In the other cases (unfit or elderly patients), therapeutic options are limited with no consensual regimen. The poly-chemotherapy by (R)-GEMOX is associated with anti-tumor activity in systemic lymphomas and a favorable toxicity profile. Our objective was to evaluate the activity and tolerance of (R)-GEMOX in PCNSL patients enrolled in the French nation-wide LOC cohort. We retrospectively analyzed all refractory or recurrent patients included in the LOC network who benefited from (R)-GEMOX (rituximab 375 mg/m
Identifiants
pubmed: 30535802
doi: 10.1007/s00277-018-3564-6
pii: 10.1007/s00277-018-3564-6
doi:
Substances chimiques
Organoplatinum Compounds
0
Deoxycytidine
0W860991D6
Rituximab
4F4X42SYQ6
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM